These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 30354009)
1. Structure-based pharmacophore models to probe anticancer activity of inhibitors of protein kinase B-beta (PKB β). Akhtar N; Jabeen I; Jalal N; Antilla J Chem Biol Drug Des; 2019 Mar; 93(3):325-336. PubMed ID: 30354009 [TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. Vyas VK; Ghate M; Goel A J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201 [TBL] [Abstract][Full Text] [Related]
3. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ). Davis GD; Vasanthi AH Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling, virtual screening, and molecular docking studies for discovery of novel Akt2 inhibitors. Fei J; Zhou L; Liu T; Tang XY Int J Med Sci; 2013; 10(3):265-75. PubMed ID: 23372433 [TBL] [Abstract][Full Text] [Related]
5. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold. Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents. Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320 [TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors. Sharma A; Thelma BK J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362 [TBL] [Abstract][Full Text] [Related]
8. Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors. Dong X; Zhou X; Jing H; Chen J; Liu T; Yang B; He Q; Hu Y Eur J Med Chem; 2011 Dec; 46(12):5949-58. PubMed ID: 22027102 [TBL] [Abstract][Full Text] [Related]
9. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750 [TBL] [Abstract][Full Text] [Related]
10. Involvement of Akt2/protein kinase B β (PKBβ) in the 8-Cl-cAMP-induced cancer cell growth inhibition. Choi KY; Ahn YH; Ahn HW; Cho YJ; Hong SH J Cell Physiol; 2013 Apr; 228(4):890-902. PubMed ID: 23018889 [TBL] [Abstract][Full Text] [Related]
11. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach. Pardhi T; Vasu K J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601 [TBL] [Abstract][Full Text] [Related]
12. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches. Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102 [TBL] [Abstract][Full Text] [Related]
13. AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery. Halder AK; Cordeiro MNDS Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920446 [TBL] [Abstract][Full Text] [Related]
14. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3). Kaur M; Silakari O J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281 [TBL] [Abstract][Full Text] [Related]
15. Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer. Akhtar N; Jabeen I Curr Cancer Drug Targets; 2018; 18(9):830-846. PubMed ID: 28669343 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of novel Akt1 inhibitors as anticancer agents using virtual co-crystallized pharmacophore generation. Al-Sha'er MA; Mansi I; Almazari I; Hakooz N J Mol Graph Model; 2015 Nov; 62():213-225. PubMed ID: 26485540 [TBL] [Abstract][Full Text] [Related]
18. Discovery of Che J; Dai X; Gao J; Sheng H; Zhan W; Lu Y; Li D; Gao Z; Jin Z; Chen B; Luo P; Yang B; Hu Y; He Q; Weng Q; Dong X J Med Chem; 2021 Aug; 64(16):12163-12180. PubMed ID: 34375113 [TBL] [Abstract][Full Text] [Related]
19. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease. Iqbal S; Anantha Krishnan D; Gunasekaran K J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053 [TBL] [Abstract][Full Text] [Related]
20. A 2D-QSAR and Grid-Independent Molecular Descriptor (GRIND) Analysis of Quinoline-Type Inhibitors of Akt2: Exploration of the Binding Mode in the Pleckstrin Homology (PH) Domain. Akhtar N; Jabeen I PLoS One; 2016; 11(12):e0168806. PubMed ID: 28036396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]